BLTE Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -112.81%. Belite Bio, Inc.'s return on equity of -37.13% beat Ionis Pharmaceuticals, Inc.'s return on equity of -67.97%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 10.23%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $93.81 which suggests that it could grow by 14.46%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.536%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $203M. Belite Bio, Inc.'s net income of -$21.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$229M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 14.40x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of 75.06%. Belite Bio, Inc.'s return on equity of -37.13% beat Ligand Pharmaceuticals, Inc.'s return on equity of 14.07%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 10.23%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $244.56 which suggests that it could grow by 20.74%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.687%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $59.7M. Belite Bio, Inc.'s net income of -$21.7M is lower than Ligand Pharmaceuticals, Inc.'s net income of $44.8M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 34.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 15.28x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -1144.46%. Belite Bio, Inc.'s return on equity of -37.13% beat Ocugen, Inc.'s return on equity of -345.08%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 10.23%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 363.92%. Given that Ocugen, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ocugen, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 2.750, suggesting its more volatile than the S&P 500 by 175.048%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Belite Bio, Inc.'s net income of -$21.7M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 106.48x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of --. Belite Bio, Inc.'s return on equity of -37.13% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 10.23%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $58.11 which suggests that it could grow by 38.26%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of -0.305, suggesting its less volatile than the S&P 500 by 130.486%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Terns Pharmaceuticals, Inc. quarterly revenues of --. Belite Bio, Inc.'s net income of -$21.7M is higher than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.